安聯全球生物科技基金-A配息類股(歐元)
192.06歐元2.13(1.12%)
2023/12/05更新
此基金於一九九八年一月成立。目標是透過投資從事研究、開發或生產生物科技、藥物或醫學科技的跨國公司,實現長期資本增值。
大型 | |||
---|---|---|---|
中型 | |||
小型 | |||
價值型 | 均衡型 | 增長型 |
Mr. Pirsch is a senior portfolio manager, a senior analyst and a director with Allianz Global Investors, which he joined in 2018. He has management and research responsibilities for the Health Care team. Mr. Pirsch has 20 years of investment-industry experience. He previously worked at Aptigon Capital, Visium Asset Management, Surveyor Capital, Fred Alger Management and C.R. Bard. Before that, Mr. Pirsch was an associate director at UBS Investment Bank and an analyst at Wells Fargo. He has a B.A. in economics and international relations from Bucknell University, and an M.B.A. with a certificate in health sector management from Duke University, Fuqua School of Business. Mr. Pirsch is a CFA charterholder.